___

• ANELL, A. “Priority setting for pharmaceuticals: the use of health economic evidence by reimbursement and clinical guidance committees” The European Journal of Health Economics, Vol. 5 (1), 2004, s. 2835.
• BALTUSSEN, R. “Priority setting of public spending in developing countries: Do not try to do everything for everybody”, Health Policy, 78, 2006, s. 149–156.
• BALTUSSEN, R. ve NIESSEN, L. “Priority setting of health interventions: the need for multi-criteria decision analysis”, Cost Effectiveness and Resource Allocation, 4:14, 2006, s. 1-9.
• BROUWER, W. B. F. vd. “Welfarism vs. extra-welfarism”, Journal of Health Economics, 27, 2008, s. 325-338.
• COAST, J. “Is economic evaluation in touch with society's health values?”, British Medical Journal, 329, 2004, s. 1233-1236.
• COAST, J. vd. “Welfarism, extra-welfarism and capability: The spread of ideas in health economics”, Social Science and Medicine, 67, 2008, s. 1190-1198.
• CORNAGO, D. vd. “Pharmacoeconomic studies in Italy: a critical review of the literature”, The European Journal of Health Economics, Vol. 8, 2007, s. 89-95.
• CORNUZ, J. vd. “Cost-effectiveness analysis of the first-line therapies for nicotine dependence”, European Journal of Clinical Pharmacology, 59 (3), 2003, s. 201-206.
• COX, H. L. “Economic evaluation in critical care medicine”, Journal of Critical Care, 21, 2006, s. 117-124.
• CUNNINGHAM, S. J. “Economic evaluation of healthcare - is it important to us?”, British Dental Journal, Vol.188 (5), 2000, s. 250254.
• DRUMMOND, M. F. vd. Methods for the Economic Evaluation of Health Care Programmes, New York, Oxford Medical Publications, 2005.
• DRUMMOND, M. F. vd. “Economic evaluation”, Singapore Med. Journal, 47(6), 2006, s. 456-461.
• FOLLAND, S. vd. The Economics of Health and Health Care, New York, Pearson Prentice Hall, 2006.
• FOX-RUSHBY, J. A., ve HANSON, K. “Calculating and presenting disability adjusted life years (DALYs) in cost-effective analysis”, Health Policy and Planning, 16 (3), 2001, s. 326-331.
• GAFNI, A. ve BIRCH, S. “Incremental cost-effectiveness ratios (ICERs): The silence of the lambda” Social Science and Medicine, 62, 2006, s. 2091-2100.
• GARBER, A. “Advances in cost-effectiveness analysis of health interventions”, NBER Working Paper Series, No: 7198, 1999, http://www.nber.org/papers/w7198.
• GARBER, A. M. ve PHELPS, C. E. “Economic foundations of costeffectiveness analysis”, Journal of Health Economics, 16, 1997, s. 131.
• GOODACRE, S. ve McCABE, C. “An introduction to economic evaluation”, The Emergency Medicine Journal, 19, 2002, s. 198-201.
• HAM, C. “Priority setting in health care: learning from international experience”, Health Policy, 42, 1997, s. 49-66.
• HAUCK, K. vd. “The Economics of Priority Setting for Health Care: A Literature Review”, HNP Discussion Paper, Washington, The World Bank. 2004.
• HURLEY, J. “An Overview of the Normative Economics of the Health Sector”, Culyer, A. J. ve Newhouse, J. P. (der.) Handbook of Health Economics içinde, Elsevier, Amsterdam, 2000, s. 55-110.
• JÖNSSON, B. “Economic evaluation for pharmaceuticals in Germany”, The European Journal of Health Economics, 8 (Suppl. 1), 2007, s. 12.
• KAMATH, C. C. vd. “The Cost-effectiveness of acetaminophen, NSAIDs, and selective COX-2 inhibitors in the treatment of symptomatic knee osteoarthritis”, Value in Health, Vol. 6 (2), 2001, s.144-157.
• KAPIRIRI, L. ve NORHEIM, O. F. “Criteria for priority-setting in health care in Uganda: exploration of stakeholders’ values”, Bulletin of the World Health Organization, 82 (3), 2004, s. 172-179.
• KERNICK, D. “An introduction to the basic principles of health economics for those involved in the development and delivery of headache care”, Cephalalgia, 25, 2005, s. 709–714.
• KLARMAN, H. E. vd. “Cost-effectiveness analysis applied to the treatment of chronic renal disease”, Medical Care, 6, 1968, s. 48–54.
• KORTHALS-DE BOS, I. B. C. vd. “Cost-effectiveness of physiotherapy, manual therapy, and general practitioner care for neck pain: economic evaluation alongside a randomized controlled trial”, British Medical Journal, Vol. 326, 2003, s. 1-6.
• MELTZER, D. “Accounting for future costs in medical costeffectiveness analysis”, Journal of Health Economics, 16 (1), 1997, s. 33-64.
• MITTON, C. R. “Priority setting for decision makers: using health economics in practice”, The European Journal of Health Economics, Vol. 3, No. 4, 2002, s. 240-243.
• OECD Health a Glance OECD Indicators, Geneva, OECD, 2007.
• PLEVRITIS, S. K. vd. “Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs. X-ray mammography of women at a high familial risk of breast cancer”, British Journal of Cancer, 95, 2006, s. 801-810.
• ROBERTSON, M. C. vd “Effectiveness and economic evaluation of a nurse delivered home exercise programme to prevent falls. 1: Randomized controlled trial”, British Medical Journal, Vol. 322, 2001, s. 1-6.
• ROBINSON, R. “Limits to rationality: economics, economists and priority setting”, Health Policy, 49, 1999, s. 13-26.
• SABIK, L.M. ve LIE, K. R. “Priority setting in health care: Lessons from the experiences of eight countries”, International Journal for Equity in Health, 7:4, 2008, s. 1-13.
• SCULPHER, M. vd. “It’s just evaluation for decision making: recent developments in, and challenges for, cost-effectiveness research”, Smith, P. C. vd. (der.) Health Policy and Economics: Opportunities and Challenges içinde, McGrawHill, Glasgow, 2005, s. 8-41.
• VERKERK, M. A. vd “Health-related quality of life research and the capability approach of Amartya Sen”, Quality of Life Research, Vol. 10 (1), 2001, s. 49-55.
• WEINSTEIN, M. C. ve MANNING, W. G. Jr. “Theoretical issues in cost-effectiveness analysis”, Journal of Health Economics, 16, 1997, s. 121-128.
• WHO The World Health Report 2000 - Health Systems: Improving Performance, WHO, Geneva, 2000.